1 / 23

Presented By William Tap at 2014 ASCO Annual Meeting

<br /> A Pilot Study of PLX3397, a Selective Colony-Stimulating Factor 1 Receptor (CSF1R) Kinase Inhibitor, in Pigmented Villonodular Synovitis (PVNS) . Presented By William Tap at 2014 ASCO Annual Meeting. Pigmented Villonodular Synovitis (PVNS)<br />Tenosynovial Giant Cell Tumor (TGCT).

noreen
Télécharger la présentation

Presented By William Tap at 2014 ASCO Annual Meeting

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. <br /> A Pilot Study of PLX3397, a Selective Colony-Stimulating Factor 1 Receptor (CSF1R) Kinase Inhibitor, in Pigmented Villonodular Synovitis (PVNS) Presented By William Tap at 2014 ASCO Annual Meeting

  2. Pigmented Villonodular Synovitis (PVNS)<br />Tenosynovial Giant Cell Tumor (TGCT) Presented By William Tap at 2014 ASCO Annual Meeting

  3. Pigmented Villonodular Synovitis (PVNS) Presented By William Tap at 2014 ASCO Annual Meeting

  4. Slide 4 Presented By William Tap at 2014 ASCO Annual Meeting

  5. Can we help patients (PVNS) <br />with a highly targeted therapy (PLX3397)<br />that blocks the CSF1R pathway <br />in this clonal neoplastic process frequently<br />initiated by a single genetic event? Presented By William Tap at 2014 ASCO Annual Meeting

  6. Study Goals Presented By William Tap at 2014 ASCO Annual Meeting

  7. Study Design Presented By William Tap at 2014 ASCO Annual Meeting

  8. Efficacy Assessments Presented By William Tap at 2014 ASCO Annual Meeting

  9. Tumor Volume Score (TVS) Presented By William Tap at 2014 ASCO Annual Meeting

  10. Patient Disposition Presented By William Tap at 2014 ASCO Annual Meeting

  11. Patient Characteristics: Safety Population (n=23) Presented By William Tap at 2014 ASCO Annual Meeting

  12. Safety: PVNS Expansion Cohort AEs<br />n = 23 Safety Population Presented By William Tap at 2014 ASCO Annual Meeting

  13. Treatment-Related AEs ≥ Grade 3 Presented By William Tap at 2014 ASCO Annual Meeting

  14. Duration of Treatment (DOT), April 2014 data cutoff:<br />Median 256 days (range 21-585 days) Presented By William Tap at 2014 ASCO Annual Meeting

  15. 14 patients evaluable with TVS Presented By William Tap at 2014 ASCO Annual Meeting

  16. Slide 16 Presented By William Tap at 2014 ASCO Annual Meeting

  17. Slide 17 Presented By William Tap at 2014 ASCO Annual Meeting

  18. Slide 18 Presented By William Tap at 2014 ASCO Annual Meeting

  19. Slide 19 Presented By William Tap at 2014 ASCO Annual Meeting

  20. Slide 20 Presented By William Tap at 2014 ASCO Annual Meeting

  21. Slide 21 Presented By William Tap at 2014 ASCO Annual Meeting

  22. Conclusions Presented By William Tap at 2014 ASCO Annual Meeting

  23. Thank You Presented By William Tap at 2014 ASCO Annual Meeting

More Related